Journal of Ayurveda and Integrative Medicine最新文献

{"title":"Eighteen months of non-union of an upper third tibial fracture treated with Ayurvedic herbal medicines and Panchakarma: A case report","authors":"Sadanand P. Sardeshmukh ,&nbsp;Sharad Hardikar ,&nbsp;S. Prakash ,&nbsp;Ranjit G. Nimbalkar ,&nbsp;Anil T. Pawar ,&nbsp;Akshay M. Baheti ,&nbsp;Manasi R. Nimbalkar","doi":"10.1016/j.jaim.2024.101105","DOIUrl":"10.1016/j.jaim.2024.101105","url":null,"abstract":"<div><div>In the present case, a 29-year-old male met with a road traffic accident and sustained a closed comminuted fracture of the upper third (U/3) of the tibia of his left leg. The patient was operated (Open Reduction Internal Fixation, ORIF) with internal nailing. Even after 18 months, the fracture line was visible in the X-ray, so he was re-operated (ORIF) and the nail was replaced by plate fixation. However, after the second operation, the patient developed foot drop and hyperesthesia due to peroneal nerve injury. In view of this complicated history, the patient was suggested to take supportive Ayurvedic medicines and <em>Panchakarma</em> to hasten the healing process. The Ayurvedic medicines <em>Lakshadi guggul</em> 500 mg, <em>Mashadi Yoga</em> 500 mg and <em>Asthi majja yoga</em> 500 mg three times a day were started. The follow-up X-ray examination after eight months of treatment didn't show considerable callus at the fracture site, so <em>P</em><em>anchakarma</em> therapy was given for 21 days. Callus formation was seen within 3 weeks after completing <em>P</em><em>anchakarma</em> treatment. The oral medications were continued and a follow-up X-ray examination on two more months of treatment showed near complete healing (Fracture line was obliterated because of considerable callus). The medicine was continued for two more months. Afterwards, the patient came back after one year and the follow-up X-ray examination showed complete healing. The internal plate was removed and complete fracture recovery was reported. Thus, a patient with a non-union fracture of the tibia was treated successfully with add-on Ayurvedic medicines and <em>P</em><em>anchakarma</em> therapy.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101105"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Lekhan Basti and Navak Guggul on lipid markers and transcriptional effects of selected genes in obese patients: A single-centre, open-labelled, randomized, comparative, pilot study","authors":"Renuka Munshi,&nbsp;Falguni Panchal,&nbsp;Dipti Kumbhar","doi":"10.1016/j.jaim.2025.101129","DOIUrl":"10.1016/j.jaim.2025.101129","url":null,"abstract":"<div><h3>Background</h3><div>Ayurveda recommends an integrative approach of <em>shodhana</em> &amp; <em>shamana</em> therapy for Obesity management.</div></div><div><h3>Objective</h3><div>This study evaluated the safety and efficacy of <em>Navak Guggul</em> and <em>Lekhan Basti,</em> individually and in combination, with respect to anthropometric, biochemical levels and transcriptional profiling of selected candidate genes in obese participants.</div></div><div><h3>Material and methods</h3><div>Single-centre, open-labelled, randomized, comparative, pilot study was conducted following Institutional Ethics Committee approval. 64 obese participants of either gender, aged between 25 and 60 years with BMI 28–32.9 kg/m² and WHR (Men&gt;0.90 and Women&gt;0.85) were randomly allocated to four groups, each with 16 participants, to receive either <em>Navak Guggul</em> or <em>Lekhan Basti,</em> individually or in combination or no treatment in addition to diet and lifestyle modification. Anthropometric measurements, ayurvedic symptoms severity score, impact of weight on quality of life (IWQOL), biochemical tests and genetic expressions of select genes (UCP2, AD1POR1, FTO, GHRL, Leptin and PPARγ) were assessed at baseline (V1), immediately after therapy (V4) and 2 months post-therapy (V6).</div></div><div><h3>Results</h3><div>50 participants completed the study. Participants from all groups showed significant reduction in BMI (except Group IV) with significant improvement in the ayurvedic symptoms score. Improvement in the IWQOL score was seen at V4 in all groups with maximal reduction in serum lipids in Groups I and III. Transcriptional profiling revealed increased expression of UCP2, ADIPOR1 and PPARγ genes at V4 and decreased expression of FTO, Ghrelin and Leptin genes compared to V1.</div></div><div><h3>Conclusion</h3><div><em>Lekhan Basti</em> and combination therapy were beneficial in reducing anthropometric and lipid parameters. Several genes were differentially expressed immediately post-treatment suggesting their role as candidate genes in obesity management.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101129"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of yogic practices on physiological and biochemical parameters of hypertensive patients: A systematic review of clinical trials","authors":"Prakhar Tyagi,&nbsp;Khushbu Jain","doi":"10.1016/j.jaim.2024.101087","DOIUrl":"10.1016/j.jaim.2024.101087","url":null,"abstract":"<div><h3>Background</h3><div>Hypertension affects around 1.28 billion adults worldwide. If not managed properly, it can lead to life threatening conditions. While various pharmacological treatments are available, they are associated with various short- and long-term side effects. Hence it is crucial to explore alternative approaches to complement the standard medical interventions. <strong>Objective:</strong> This systematic review aims to explore the impacts of yogic practices on various physiological and biochemical parameters in hypertensive patients.</div></div><div><h3>Methods</h3><div>Various electronic databases including PubMed, Cochrane library, Directory of Open Access Journals and Google scholar were systematically searched until October 31, 2023 to collect relevant data.</div></div><div><h3>Results</h3><div>A total of 15 articles comprising 5 RCTs and 10 clinical trials were identified. The number of participants ranged between 33 and 300, with Yoga intervention lasting from two months to a year. The analyses revealed that Yogic practices, such as loosening practices, <em>Surya Namaskar</em>, <em>Tadasana, Trikonasana</em>, <em>Paschimottanasana</em>, <em>Shavasana. Anulom-Vilom Pranayama</em>, <em>Bhramari Pranayama</em>, meditation and Yoga Nidra, positively influenced physiological and biochemical markers linked to Hypertension such as autonomic nervous system activity, angiotensin II expression, oxidative stress, lipid metabolism, immune system function and inflammatory gene expression.</div></div><div><h3>Conclusion</h3><div>The findings of this systematic review indicate that the Yoga practices have a positive impact on physiological and biochemical markers associated with hypertension which may help in its proper management and treatment. Future studies need to assess additional markers associated with hypertension, such as vasopressin, adrenocorticotropic hormone, gamma-aminobutyric acid and others to enhance the understanding of the mechanism of the effects of Yoga on hypertension.</div></div><div><h3>Study registration</h3><div>PROSPERO ID: CRD42024497060.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101087"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143950448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withaferin A reduces pulmonary eosinophilia and IL-25 production in a mouse model of allergic airways disease","authors":"Kevin Agner ,&nbsp;Victoria L. McQuade ,&nbsp;Jack Womble ,&nbsp;Marissa A. Guttenberg ,&nbsp;Sanat Phatak ,&nbsp;Jennifer L. Ingram","doi":"10.1016/j.jaim.2025.101144","DOIUrl":"10.1016/j.jaim.2025.101144","url":null,"abstract":"<div><h3>Background</h3><div>Several studies report that ashwagandha, a traditional Ayurvedic supplement, has anti-inflammatory properties. Type 2 (T2) asthma is characterized by eosinophilic airway inflammation.</div></div><div><h3>Objective</h3><div>We hypothesized that allergen-induced eosinophilic airway inflammation in mice would be reduced following administration of Withaferin A (WFA), the primary active phytochemical in Ashwagandha.</div></div><div><h3>Materials and Methods</h3><div>C57BL/6J mice were given 10 total intra-peritoneal injections of 2 mg/kg WFA or vehicle control, concurrent with 6 total intranasal administrations of 50 μg house dust mite extract (HDM) or saline control over 2 weeks.</div></div><div><h3>Results</h3><div>We observed that treatment with WFA reduced allergen-induced peribronchial inflammation and airway eosinophil counts compared to mice treated with controls. In addition, we observed that treatment with WFA reduced lung levels of interleukin-25 (IL-25) but increased lung gene expression levels of its co-receptor, <em>Il17ra</em>, in HDM-challenged mice compared to HDM-challenged mice that received the vehicle control.</div></div><div><h3>Conclusion</h3><div>This study pinpoints a potential mechanism by which WFA modulates allergen-induced airway eosinophilia via the IL-25 signaling pathway. Future studies will investigate the effects of WFA administration on lung eosinophilia and IL-25 signaling in the context of chronic allergen-challenge.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101144"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144184647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aam assessment in the clinical practice of ayurveda: Outlining the process and predicting the outcomes","authors":"Sanjeev Rastogi,&nbsp;Preeti Pandey","doi":"10.1016/j.jaim.2025.101126","DOIUrl":"10.1016/j.jaim.2025.101126","url":null,"abstract":"","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101126"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of Yogic Personal Excellence Inventory","authors":"Rudra B. Bhandari,&nbsp;Nidhi Chaudhry","doi":"10.1016/j.jaim.2024.101122","DOIUrl":"10.1016/j.jaim.2024.101122","url":null,"abstract":"<div><h3>Background</h3><div>In his <em>Yoga Sutras</em>, Patanjali delineates the principles, processes, practices, and impediments of personal excellence (PE). Unlike Patanjali's perspective, existing conceptualizations and measures of PE are centered on quantifying well-being, leadership effectiveness, professional competence, academic and sports performance, and motivation. However, no yoga-based operationalized model or measure of PE exists to date.</div></div><div><h3>Objectives</h3><div>This study aimed to develop and validate a novel self-report yogic personal excellence inventory (YPEI) with constructs derived from the PYS.</div></div><div><h3>Materials and methods</h3><div>The research was conducted in three rigorous phases to establish YPEI's reliability and validity. Firstly, the YPEI's items were framed and validated for their content by ten experts. Secondly, the first draft of the YPEI was administered to 721 participants for exploratory factor analysis (EFA). The YPEI was then administered to 364 participants to confirm the explored factor structure. Lastly, YPEI's inter-instrument convergent and discriminant validity were assessed by computing correlation with three criteria measures―the <em>vikruti subdosha</em> questionnaire, the <em>vedic</em> personality inventory, and the personal efficacy scale.</div></div><div><h3>Conclusion</h3><div>The model was a good fit with eight factors (psychic incompetence, attachment, despair, existential thinking, somatic illness, laziness, indulgence, and instability). As hypothesized, PE was positively associated with personal efficacy and <em>vedic</em> personality but negatively with <em>vikruti</em>. YPEI will be applicable to measure the psychic and physical morbidities and comorbidities of healthy/unhealthy individuals and prescribe the required personalized bio-psycho-socio-spiritual protocol to minimize them and maximize PE.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101122"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144204583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ashwagandha, Withania somnifera (L.) Dunal, for the prophylaxis against SARS-CoV-2 infection: A multicentric randomized hydroxychloroquine controlled clinical trial in Indian health care workers","authors":"Renuka Kulkarni-Munshi ,&nbsp;Deepti Talmohite ,&nbsp;Anand More ,&nbsp;Jaya Chakravarty ,&nbsp;Sandhya Kamat ,&nbsp;Akash Khobragade ,&nbsp;D. Himanshu Reddy ,&nbsp;Manish Patel ,&nbsp;Divya Kajaria ,&nbsp;Raju Singh ,&nbsp;Sarita Kumari ,&nbsp;Priyanka Mishra ,&nbsp;A.K. Srivastava ,&nbsp;Vivek Bhagat ,&nbsp;Saurabh Pandey ,&nbsp;Meena Yadav ,&nbsp;Rahul Darnule ,&nbsp;Shobha Bhat ,&nbsp;Sangeeta Kansal ,&nbsp;Sonali Munot ,&nbsp;Arvind Chopra","doi":"10.1016/j.jaim.2025.101135","DOIUrl":"10.1016/j.jaim.2025.101135","url":null,"abstract":"<div><h3>Background</h3><div>The study was planned when, the hydroxychloroquine (HCQ) was the only prophylactic agent approved by health authorities in several countries and no prophylactic COVID-19 vaccine was available.</div></div><div><h3>Objective</h3><div>The present study aimed to evaluate efficacy of <em>Withania Somnifera (L.) Dunal</em> (<em>WS</em>) as a chemoprophylactic and immunomodulatory agent against SARS-CoV-2 infection.</div></div><div><h3>Methods</h3><div>In a 12 week, randomized, open label, parallel group, two arm, comparative, multicentric, controlled trial compared <em>WS</em> with hydroxychloroquine (HCQ) in health care workers (HCWs). Total 400 HCWs were randomized in 1:1 ratio to receive either oral <em>WS</em> (500 mg for 12 weeks) or HCQ 400 mg (for 7 weeks). The primary outcome was to establish equivalence between <em>WS</em> and HCQ for the proportion of participants contracting SARS-CoV-2 infection.</div></div><div><h3>Results</h3><div>Seven participants contracted SARS-CoV-2 infection: 5 in <em>WS</em> arm and 2 in HCQ arm. The equivalence between <em>WS</em> and HCQ was established for the proportion difference of participants contracting SARS-CoV-2 infection for per-protocol (PP) (1.6%, 95% CI: −1.08%–4.33%) and in subgroup analysis (ITT, mIIT, non-vaccinated and seronegative).</div><div>Notably, the immunomodulatory effect of <em>WS</em> stood scientifically validated by the statistically significant difference in cytokine levels (<em>p</em> &lt; 0.0001) at 12 weeks compared to baseline for Tumor Necrosis Factor (TNF)-alpha, Interleukin (IL)-2, IL-10, IL-17 and Monocyte chemoattractant protein-1 (MCP-1).</div><div>Gastrointestinal-related AEs were most frequent (53 in <em>WS</em> and 58 in HCQ). Headache and sneezing were observed only with HCQ. Participant global assessment showed excellent tolerability with both treatment arms.</div></div><div><h3>Conclusion</h3><div><em>WS</em> was found equivalent to HCQ as a prophylactic against SARS-CoV-2 infection with no safety concern. <em>WS</em> is thus inferred to be an effective and safe Ayurvedic intervention for prophylaxis against SARS-CoV-2 infection, and also as an immunobooster.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101135"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Export of evidence-based wellness services: An opportunity to actualize India's demographic dividend","authors":"Rakesh Sarwal ,&nbsp;Hemant Bhargav ,&nbsp;Badri Narayanan Gopalakrishnan","doi":"10.1016/j.jaim.2025.101153","DOIUrl":"10.1016/j.jaim.2025.101153","url":null,"abstract":"<div><div>India's demographic dividend offers a critical opportunity to drive sustained economic growth over the next three decades, driven by increasing its share in global trade. Up until 1700, India had a thriving industrial manufacturing economy, producing about 25 % of the world's industrial output, making it the most important manufacturing centre in international trade. Based on recent trends, we argue that the service sector presents considerable growth potential. Within the service sector, despite a small share currently, the healthcare and wellness demonstrate particular promise. Leveraging India's vast pool of trained professionals and its established expertise in traditional systems of medicine, notably AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy), suitable governmental initiatives are needed based on a strategy and a road map to incentivize exporters, get international recognition of Indian certifications, particularly by developed nations. This is essential for the growth of the export of wellness services from India, but can also help reduce the burgeoning healthcare costs, inequity and address the needs of ageing populations in developed countries.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101153"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144106000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Yoga and Ayurveda therapy for negative symptoms in schizophrenia: A case series highlighting safety and synergistic value of integrative and personalized healthcare","authors":"Kavyashree Kulamarva ,&nbsp;Varsha Karanth ,&nbsp;Chandrasena Santosh ,&nbsp;Chikkanna Umesh ,&nbsp;Hemant Bhargav ,&nbsp;Venkataram Shivakumar ,&nbsp;Kishore Kumar Ramakrishna ,&nbsp;Nishitha Jasti ,&nbsp;Shivarama Varambally","doi":"10.1016/j.jaim.2024.101092","DOIUrl":"10.1016/j.jaim.2024.101092","url":null,"abstract":"<div><div>Negative symptoms are a significant contributor to the psychopathology of schizophrenia, primarily affecting socio-occupational functioning. Though effective in managing positive symptoms, most pharmacological agents have limited effects on the negative symptoms of schizophrenia, especially the primary negative symptoms. We discuss five cases (4 males, one female, age range: 24–36 years) of chronic schizophrenia (diagnosed as per ICD-10 criteria) with duration of illness ranging from 2 to 18 years. All the cases had negative symptoms with moderate to extreme severity on the scale for assessment of negative symptoms (SANS) (scores 49 or above; range 49–82). Subjects underwent integrated yoga and ayurveda (IYA) intervention for 12 weeks. Ayurveda intervention included systematic detox <em>(Panchakarma Shodhana)</em> and pacifying herbs <em>(Shamana),</em> whereas yoga involved the practice of a previously validated yoga module. For all the subjects, anti-psychotic medications were stable for the last eight weeks and did not change during the 12-week IYA intervention and eight weeks after. Post-intervention SANS scores were reduced in all the subjects. The reduction of SANS scores ranged from −15 to −43 (average: −35.6), corresponding to CGI-I ratings of ‘much improved’ in three subjects and ‘minimally improved’ in two subjects. Clinical assessments by an independent psychiatrist at baseline, during IYA (4 weeks), immediately post-IYA (12 weeks), and eight weeks post-IYA did not reveal any new potential side effects due to IYA or worsening of other clinical symptoms or exaggeration of side effects of antipsychotics. This needs further scientific exploration through systematic clinical and mechanistic trials in the future.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101092"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ayurvedic management of chemotherapy induced adverse effects in sigmoid colon carcinoma - a case report","authors":"P. Divya","doi":"10.1016/j.jaim.2024.101112","DOIUrl":"10.1016/j.jaim.2024.101112","url":null,"abstract":"<div><div>Colorectal cancer is one among the leading causes of death in the present world. Either the adverse effects of the chemotherapeutic drugs force the patients to discontinue the treatment or the deteriorated health status due to progression of the disease may lead to death. This is the study of a case of stage 3 sigmoid colon cancer which was managed by an integrated approach and led to the heathy survival of the patient after five years. Ayurvedic management was done to alleviate the side effects of chemotherapy and for the prevention of the recurrence of the disease. The patient was treated with adjuvant chemotherapy with FOLFOX regimen and the side effects were managed by Ayurvedic medicines.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 3","pages":"Article 101112"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}